

Consolidated Statement of Cash Flows

Mitsubishi Tanabe Pharma Corporation and Consolidated Subsidiaries

(Millions of yen)

	FY 2017	FY 2018
Cash flows from operating activities:		
Profit before income tax	78,764	50,439
Depreciation and amortization	11,535	11,529
Impairment losses	3,791	17
Interest and dividend income	(1,238)	(1,144)
Share of loss (profit) of associates and joint ventures accounted for using equity method	(23)	80
Loss (gain) on sales of property, plant and equipment	(2,287)	(13)
Loss (gain) on sales of investments in subsidiaries	(3,565)	–
Restructuring loss	2,144	5,695
Decrease (increase) in trade and other receivables	(6,111)	6,567
Decrease (increase) in inventories	(2,683)	6,641
Increase (decrease) in trade and other payables	56	(4,728)
Increase (decrease) in provisions	2,529	(1,974)
Decrease (increase) in net defined benefit assets	1,153	193
Increase (decrease) in net defined benefit liabilities	(948)	(253)
Increase (decrease) in deferred income	(480)	(687)
Other	(2,965)	3,600
Subtotal	79,672	75,962
Interest received	522	555
Dividends received	772	688
Interest paid	(160)	(222)
Income taxes paid	(13,863)	(35,523)
Net cash flows provided by operating activities	66,943	41,460
Cash flows from investing activities:		
Payments into time deposits	(3,742)	(1,709)
Proceeds from withdrawal of time deposits	8,407	5,220
Purchase of property, plant and equipment	(6,416)	(5,730)
Proceeds from sales of property, plant and equipment	3,703	91
Purchase of intangible assets	(22,034)	(3,777)
Purchase of investments	(391,749)	450,669
Proceeds from sales and redemption of investments	428,741	422,367
Proceeds from withdrawal of deposits	70,000	–
Proceeds from sales of subsidiaries	10,803	–
Purchase of subsidiaries	(119,724)	–
Proceeds from transfer of business	3,000	3,000
Other	(167)	(5)
Net cash flows used in investing activities	(19,178)	(31,212)
Cash flows from financing activities:		
Purchase of treasury shares	(549)	(1)
Proceeds from stock issuance to non-controlling interests	5,409	6,276
Dividends paid	37,017	(31,403)
Other	(344)	(741)
Net cash flows used in financing activities	(32,501)	(25,869)
Effect of exchange rate changes on cash and cash equivalents	(1,457)	531
Net increase (decrease) in cash and cash equivalents	13,807	(15,090)
Increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale	8	(90)
Cash and cash equivalents at the beginning of the year	113,215	127,030
Cash and cash equivalents at the end of the year	127,030	111,850